Evidence map›Paper›PMID 42393925›Full record

ArticleClinical genetics2026

Genetic Spectrum of Non-PTPN11 Variants in Noonan Syndrome and Related RASopathies: Findings From a Russian Cohort.

Anna Orlova, Olga Shatokhina, Daria Guseva, Nina Demina, Aleksander Polyakov, Oхana Ryzkova

Abstract read
In one paragraph

Article in Clinical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anna OrlovaFederal State Budgetary Scientific Institution "Research Centre for Medical Genetics", Moscow, Russia.ORCID https://orcid.org/0000-0002-8831-1844
Olga ShatokhinaFederal State Budgetary Scientific Institution "Research Centre for Medical Genetics", Moscow, Russia.ORCID https://orcid.org/0000-0003-0351-1271
Daria GusevaFederal State Budgetary Scientific Institution "Research Centre for Medical Genetics", Moscow, Russia.
Nina DeminaFederal State Budgetary Scientific Institution "Research Centre for Medical Genetics", Moscow, Russia.
Aleksander PolyakovFederal State Budgetary Scientific Institution "Research Centre for Medical Genetics", Moscow, Russia.
Oхana RyzkovaFederal State Budgetary Scientific Institution "Research Centre for Medical Genetics", Moscow, Russia.ORCID https://orcid.org/0000-0003-1285-9093

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Noonan syndrome (NS) and related RASopathies form a clinically and genetically heterogeneous group of disorders caused by germline dysregulation of the RAS/MAPK pathway. Pathogenic variants in PTPN11 account for roughly half of classical NS, but the contribution of non-PTPN11 genes in patients referred with NS or Noonan-like phenotypes remains incompletely defined in several populations, including Russia. We characterized the spectrum of non-PTPN11 variants in a large Russian cohort referred for suspected NS or Noonan-like phenotypes and examined gene-specific clinical patterns. We analyzed 456 unrelated patients with clinically diagnosed NS or Noonan-related syndromes using a targeted panel of 23 RAS/MAPK pathway genes. PTPN11 variants (23% of cases) were reported previously; here we focused on the remaining patients. Pathogenic or likely pathogenic variants were identified in 19% of cases (85/456), with NF1, SOS1, SHOC2, and BRAF being the most frequently mutated genes, together accounting for 50% of the non-PTPN11 diagnoses. Novel variants were observed in 12.1% of cases (7/58 unique variants). Several genotype-phenotype associations emerged: SOS1 mutations were associated with a high prevalence of cardiac defects, especially pulmonary stenosis and atrial septal defects (64% of patients, p = 0.01), whereas NF1 and SPRED1 cases had significantly fewer cardiac anomalies (p < 0.001 and p < 0.05, respectively). Lentigines were predominantly seen in NF1 and SPRED1 patients (p < 0.01), and all three evaluable males with MAP2K1 variants had cryptorchidism (3/3). Conversely, BRAF-mutated patients showed lower incidence of chest deformity (p < 0.01) but higher rates of developmental delay. NF1, SOS1, SHOC2, and BRAF together accounted for half of the non-PTPN11 molecular diagnoses in this Russian cohort, and the observed gene-specific clinical patterns align with previous series, although limited subgroup sizes preclude firm individual associations.

Indexed as

Noonan SyndromeProtein Tyrosine Phosphatase, Non-Receptor Type 11ras ProteinsAdolescentAdultChildChild, PreschoolCohort StudiesFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHumansInfantIntracellular Signaling Peptides and ProteinsMaleMutationBRAF protein, humanIntracellular Signaling Peptides and ProteinsProtein Tyrosine Phosphatase, Non-Receptor Type 11Proto-Oncogene Proteins B-rafPTPN11 protein, humanras ProteinsSHOC2 protein, humanSOS1 ProteinSOS1 protein, humangenotype–phenotype correlationmutation spectrumnon‐PTPN11 variantsNoonan‐like phenotypeNoonan syndromeRASopathies

Identifiers

PMID42393925
PMCPMC13631069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.